Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04833426
Other study ID # NL7436209120
Secondary ID 2020-003012-2720
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 12, 2022
Est. completion date December 2027

Study information

Verified date March 2024
Source Canisius-Wilhelmina Hospital
Contact Joost van Drumpt, MSc
Phone +31243658190
Email enforce@cwz.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sexual dysfunction is a common side effect of radical prostatectomy (RP) and has a significant negative impact on quality of life. With age the testosterone level in men declines; around 30% of men over 70 years of age meet the criteria of testosterone deficiency (TD). The negative impact of both TD and RP on sexual performance are likely to add up. The aim of this study is to assess the efficacy and safety of testosterone replacement therapy (TRT) on functional and oncological outcomes in testosterone deficient men following RP for prostate cancer (PCa).


Description:

Rationale: Radical prostatectomy (RP) is currently the most common treatment for non-metastatic prostate cancer (PCa). Two frequent side effects of this procedure are urinary incontinence and erectile dysfunction, both having a significant negative impact on quality of life. Additionally, it is known that with age the testosterone level in men declines. This does not lead to symptoms in all men (asymptomatic testosterone deficiency). Both testosterone deficiency (TD) and radical prostatectomy are well-established to have a significant negative impact on sexual performance and are likely to add up in patients with a low testosterone following RP. Objective: The aim of this study is to assess the effect of testosterone replacement therapy (TRT) on functional and oncological outcomes in testosterone deficient men following RP for PCa. Study design: This study is a phase 3 prospective, randomized, placebo-controlled, single-blind clinical trial. Study population: All men over 18 years old diagnosed with non-metastatic prostate cancer who are scheduled for RP within three months as primary treatment, can be prescreened for inclusion. Prior to the RP, serum testosterone will be determined. Subsequently, within six weeks after the RP, serum testosterone will be determined again and patients will be screened for inclusion. If necessary, a third measurement of testosterone will be done. Eligible patients meet the criteria for TD and other inclusion criteria. Intervention: Patients will be randomized for testosterone replacement therapy (TRT) or placebo as a daily administered topical gel starting within 8 weeks after RP. Patients will receive TRT or placebo for one year following RP and will be monitored for another year for functional outcomes and for four more years to establish 5-year biochemical recurrence (BCR) free survival. Main study parameters/endpoints: The primary study endpoint is a clinically relevant (12 points or more) difference in the EPIC-26 domain for sexual functioning 12 months after RP in favor of testosterone deficient men receiving TRT compared with testosterone deficient men receiving placebo. Secondary endpoints include: urinary incontinence score, hormonal functioning score and BCR-free survival. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The number of visits and blood drawings are equal to standard of care follow-up after RP, with the exception of two or three extra blood samples at the first prescreening visit and within six weeks following RP. We ask patients to remain with their hospital for 24 months after RP for follow-up and to complete online questionnaires for the given visits. The five-year biochemical recurrence (BCR) free survival will be obtained through patient's medical records and if insufficient, through the Dutch Cancer Registry (NKR). Patients who receive TRT or placebo can experience local side-effects such as itching, rash and/or irritation at the site of application. In addition, patients who receive TRT can experience systemic sideeffects are gain of weight, hot flashes, acne and an increase in red blood count level. Furthermore, TRT might improve sexual functioning, urinary continence, hormonal functioning and BCR-free survival, but this is not certain and is subject of research in this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date December 2027
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Unmeasurable PSA after RP 2. pT2-pT3a after RP 3. ISUP 1-3 regardless of surgical margins 4. ISUP 4-5 with negative surgical margins 5. At least one-sided nerve-sparing procedure 6. Baseline score sexual functioning domain of = 40 points (EPIC-26) Exclusion Criteria: 1. Metastatic disease (cN1/M1) 2. pT3b or pT4 after RP 3. Prior treatment for PCa 4. Prior TRT 5. Medical history of male breast- or liver carcinoma 6. Uncontrolled hypertension 7. General contra-indication for TRT 8. Allergy for components in TRT 9. Use of vitamin K-antagonists 10. BMI > 30

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Testosterone gel
Topical gel containing testosterone
Placebo
Topical gel without active substance

Locations

Country Name City State
Netherlands Jeroen Bosch Hospital 's-Hertogenbosch
Netherlands Netherlands Cancer Institute Amsterdam
Netherlands Catharina Hospital Eindhoven
Netherlands Zuyderland Heerlen
Netherlands St. Antonius Hospital Nieuwegein
Netherlands Canisius Wilhelmina Ziekenhuis Nijmegen
Netherlands Radboud university medical center Nijmegen

Sponsors (2)

Lead Sponsor Collaborator
Canisius-Wilhelmina Hospital Besins Healthcare

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinically relevant (=12 points) difference in the EPIC-26 sexual functioning domain score, 12 months after radical prostatectomy between groups. Functional recovery after radical prostatectomy will be assessed by EPIC-26 questionnaire, a Patient Reported Outcome Measure (PROM). Patients will be asked to complete this questionnaire online. 12 months
Secondary Clinically relevant (=12 points) difference in the EPIC-26 sexual functioning domain score 3 months after radical prostatectomy between groups. Clinical relevance (>12 points) for sexual function domain score as measured by EPIC-26. 3 months
Secondary Clinically relevant (=12 points) difference in the EPIC-26 sexual functioning domain score 24 months after radical prostatectomy between groups. Clinical relevance (>12 points) for sexual function domain score as measured by EPIC-26. 24 months
Secondary Clinically relevant (=9 points) difference in the EPIC-26 urinary incontinence domain score, 12 months after radical prostatectomy between groups. Clinical relevance (>9 points) for Urinary incontinence domain score as measured by EPIC-26. 12 months
Secondary Clinically relevant (=9 points) difference in the EPIC-26 urinary incontinence domain score, 24 months after radical prostatectomy between groups. Clinical relevance (>9 points) for Urinary incontinence domain score as measured by EPIC-26. 24 months
Secondary Clinically relevant (=6 points) difference in the EPIC-26 for hormonal functioning domain score, 12 months after radical prostatectomy between groups. Clinical relevance (>6 points) for hormonal functioning domain score as measured by EPIC-26. 12 months
Secondary Clinically relevant (=6 points) difference in the EPIC-26 for hormonal functioning domain score, 24 months after radical prostatectomy between groups. Clinical relevance (>6 points) for hormonal functioning domain score as measured by EPIC-26. 24 months
Secondary Difference in biochemical recurrence rate between groups. Biochemical recurrence (BCR) is defined as the occurrence of measurable (>0.1 ng/ml) prostate specific antigen (PSA), during routinely follow-up up to five years after surgery, determined at two different occasions with at least one week between them.The BCR-rate between the placebo and control group will be compared to determine the influence of testosterone therapy on BCR. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT04964271 - Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
Completed NCT02546908 - A Registry of Participants With Prostate Cancer in Asia
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT01683994 - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT04838613 - Study of Diagnostic Performance of [18F]CTT1057 in BCR Phase 3
Completed NCT02364531 - A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Completed NCT01929655 - Japanese BAY88-8223 Monotherapy Phase II Study Phase 2
Active, not recruiting NCT05022849 - A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants Phase 1
Completed NCT03261999 - Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer Phase 3
Terminated NCT04907227 - Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension Phase 3
Active, not recruiting NCT03587285 - A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT02217566 - Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy Phase 2
Not yet recruiting NCT04101305 - Measurement of Circulating Tumor Cells in Prostate Cancer
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Terminated NCT03066154 - Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer Phase 1
Withdrawn NCT02905201 - A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) N/A
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Terminated NCT01420965 - Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer Phase 2
Completed NCT01441713 - Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer N/A